HAE vs. ICUI, MMSI, IRTC, NARI, IART, GKOS, GMED, AXNX, ATRC, and NUVA
Should you be buying Haemonetics stock or one of its competitors? The main competitors of Haemonetics include ICU Medical (ICUI), Merit Medical Systems (MMSI), iRhythm Technologies (IRTC), Inari Medical (NARI), Integra LifeSciences (IART), Glaukos (GKOS), Globus Medical (GMED), Axonics (AXNX), AtriCure (ATRC), and NuVasive (NUVA). These companies are all part of the "surgical & medical instruments" industry.
Haemonetics vs.
ICU Medical (NASDAQ:ICUI) and Haemonetics (NYSE:HAE) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation, community ranking and dividends.
ICU Medical has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.
93.9% of ICU Medical shares are owned by institutional investors. 7.5% of ICU Medical shares are owned by company insiders. Comparatively, 1.7% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
ICU Medical received 16 more outperform votes than Haemonetics when rated by MarketBeat users. Likewise, 64.63% of users gave ICU Medical an outperform vote while only 60.17% of users gave Haemonetics an outperform vote.
In the previous week, Haemonetics had 7 more articles in the media than ICU Medical. MarketBeat recorded 11 mentions for Haemonetics and 4 mentions for ICU Medical. Haemonetics' average media sentiment score of 1.05 beat ICU Medical's score of 1.03 indicating that Haemonetics is being referred to more favorably in the news media.
ICU Medical presently has a consensus target price of $203.00, suggesting a potential upside of 17.18%. Haemonetics has a consensus target price of $103.17, suggesting a potential upside of 23.98%. Given Haemonetics' stronger consensus rating and higher probable upside, analysts clearly believe Haemonetics is more favorable than ICU Medical.
Haemonetics has a net margin of 9.87% compared to ICU Medical's net margin of -2.00%. Haemonetics' return on equity of 20.13% beat ICU Medical's return on equity.
Haemonetics has lower revenue, but higher earnings than ICU Medical. ICU Medical is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.
Summary
Haemonetics beats ICU Medical on 12 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HAE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Haemonetics Competitors List
Related Companies and Tools